The depletion of the Covid-19 drug comes as global coronavirus cases surge and as the US has bought up most of the drugmaker Gilead’s output.
Gilead Chief Commercial Officer Johanna Mercier said the company expects by next week to be in a position to fulfill orders coming through Europe.
She added that the pharmaceutical company will, by the end of October, be able to meet real-time global demand for remdesivir.
She said the company is working with EU regulators so that the Covid-19 drug can be distributed more widely, but without going through the country-by-country economic review process typically required before a pharmaceutical product can be sold in Europe.
In July, the 27 European Union countries and Britain, with a combined population of 500 million, secured doses to treat about 30,000 patients.
The United States signed a deal for more than 500,000 courses of treatment, accounting for most of Gilead's output through September.
"Remdesivir has run out," Dutch Health Ministry spokesman Martijn Janssen told Reuters, adding however that new deliveries were expected shortly.